About us

 

Phosplatin Therapeutics is a clinical stage pharmaceutical company developing phosphaplatins, a family of small-molecule compounds designed to replace conventional cytotoxic therapies in the treatment of cancer. 

Phosphaplatins are the result of decades of research by the inventor. Our lead compound, PT-112, is the subject of an ongoing first-in-human Phase I Clinical study.

 

 

 


Headquarters:

1350 Avenue of the Americas 3rd Fl. 

New York, NY 10019-4703

(646) 380-2441

info@phosplatin.com

 

 
about.jpg